Cargando…
Current guidelines for the management of asthma in young children
The diagnosis and management of asthma in young children is difficult, since there are many different wheezy phenotypes with varying underlying aetiologies and outcomes. This review discusses the different approaches to managing young children with wheezy illnesses presented in recently published gl...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831604/ https://www.ncbi.nlm.nih.gov/pubmed/20224672 http://dx.doi.org/10.4168/aair.2010.2.1.1 |
_version_ | 1782178259052527616 |
---|---|
author | Potter, Paul C |
author_facet | Potter, Paul C |
author_sort | Potter, Paul C |
collection | PubMed |
description | The diagnosis and management of asthma in young children is difficult, since there are many different wheezy phenotypes with varying underlying aetiologies and outcomes. This review discusses the different approaches to managing young children with wheezy illnesses presented in recently published global guidelines. Four major guidelines published since 2007 are considered. Helpful approaches are presented to assist the clinician to decide whether a clinical diagnosis of asthma can, or should be made in a young child with a recurrent wheezy illness and which treatments would be appropriate, dependent on risk factors, age of presentation, response to initial treatment and safety considerations. Each of the guidelines provide useful information for clinicians assessing young children with recurrent wheezy illnesses. There are differences in classification of the disease and treatment protocols. Although a firm diagnosis of asthma may only be made retrospectively in some cases and there are several effective guidelines to initiating treatment. Consistent review of the need for ongoing treatment with a particular pharmacological modality is essential, since many children with recurrent wheezing in infancy go into spontaneous remission. It is probable that newer biomarkers of airway inflammation will assist the clinician as to when to initiate and when to continue pharmacological treatment in the future. |
format | Text |
id | pubmed-2831604 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease |
record_format | MEDLINE/PubMed |
spelling | pubmed-28316042010-03-11 Current guidelines for the management of asthma in young children Potter, Paul C Allergy Asthma Immunol Res Review The diagnosis and management of asthma in young children is difficult, since there are many different wheezy phenotypes with varying underlying aetiologies and outcomes. This review discusses the different approaches to managing young children with wheezy illnesses presented in recently published global guidelines. Four major guidelines published since 2007 are considered. Helpful approaches are presented to assist the clinician to decide whether a clinical diagnosis of asthma can, or should be made in a young child with a recurrent wheezy illness and which treatments would be appropriate, dependent on risk factors, age of presentation, response to initial treatment and safety considerations. Each of the guidelines provide useful information for clinicians assessing young children with recurrent wheezy illnesses. There are differences in classification of the disease and treatment protocols. Although a firm diagnosis of asthma may only be made retrospectively in some cases and there are several effective guidelines to initiating treatment. Consistent review of the need for ongoing treatment with a particular pharmacological modality is essential, since many children with recurrent wheezing in infancy go into spontaneous remission. It is probable that newer biomarkers of airway inflammation will assist the clinician as to when to initiate and when to continue pharmacological treatment in the future. The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2010-01 2009-12-30 /pmc/articles/PMC2831604/ /pubmed/20224672 http://dx.doi.org/10.4168/aair.2010.2.1.1 Text en Copyright © 2010 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Potter, Paul C Current guidelines for the management of asthma in young children |
title | Current guidelines for the management of asthma in young children |
title_full | Current guidelines for the management of asthma in young children |
title_fullStr | Current guidelines for the management of asthma in young children |
title_full_unstemmed | Current guidelines for the management of asthma in young children |
title_short | Current guidelines for the management of asthma in young children |
title_sort | current guidelines for the management of asthma in young children |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831604/ https://www.ncbi.nlm.nih.gov/pubmed/20224672 http://dx.doi.org/10.4168/aair.2010.2.1.1 |
work_keys_str_mv | AT potterpaulc currentguidelinesforthemanagementofasthmainyoungchildren |